FDA clears once-daily ADHD capsule from Corium
Corium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms. Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, according to a news release.
Other Articles in this Edition
Black, Hispanic, Asian children less likely to be diagnosed, treated for ADHD
Strep Throat Doesn’t Worsen Tourette But May Affect ADHD: Study
Childhood ADHD Increases Risk Of Developing Schizophrenia Or Other Psychotic Disorders
FDA clears once-daily ADHD capsule from Corium
How Does Poor Sleep Affect Children With Autism or ADHD?
ADHD Impulse Control: 5 Tips To Help You Manage
Sensory modulation and negative affect in children at familial risk of ADHD
Navigating My Son’s A.D.H.D. Made Me Realize I Had It, Too
Resting state high gamma as a biomarker for ADHD: An MEG crossover placebo-controlled study